Evidence map›Paper›PMID 33916749›Full record

ArticleInternational journal of environmental research and public health2021

Arsenic Exposure, Arsenic Metabolism, and Glycemia: Results from a Clinical Population in New York City.

Fen Wu, Yu Chen, Ana Navas-Acien, Michela L Garabedian, Jane Coates, Jonathan D Newman

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fen WuDepartment of Population Health, New York University School of Medicine, New York, NY 10016, USA.
Yu ChenDepartment of Population Health, New York University School of Medicine, New York, NY 10016, USA.
Ana Navas-AcienDepartment of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, NY 10032, USA.ORCID 0000-0001-9824-7797
Michela L GarabedianDivision of Cardiology and the Center for the Prevention of Cardiovascular Disease, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA.
Jane CoatesDivision of Cardiology and the Center for the Prevention of Cardiovascular Disease, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA.
Jonathan D NewmanDivision of Cardiology and the Center for the Prevention of Cardiovascular Disease, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA.
New York University · USColumbia University · US

Funding

Arsenic Exposure, Diabetes and AtherosclerosisK23HL125991 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NEWMAN, JONATHAN D · 2016 to 2020
$868k
NHLBI NIH HHS K23 HL125991
6 · The paper itself

Abstract

Little information is available regarding the glycemic effects of inorganic arsenic (iAs) exposure in urban populations. We evaluated the association of total arsenic and the relative proportions of arsenic metabolites in urine with glycemia as measured by glycated blood hemoglobin (HbA1c) among 45 participants with prediabetes (HbA1c ≥ 5.7-6.4%), 65 with diabetes (HbA1c ≥ 6.5%), and 36 controls (HbA1c < 5.7%) recruited from an academic medical center in New York City. Each 10% increase in the proportion of urinary dimethylarsinic acid (DMA%) was associated with an odds ratio (OR) of 0.59 (95% confidence interval (CI): 0.28-1.26) for prediabetes, 0.46 (0.22-0.94) for diabetes, and 0.51 (0.26-0.99) for prediabetes and diabetes combined. Each 10% increase in the proportion of urinary monomethylarsonic acid (MMA%) was associated with a 1.13% (0.39, 1.88) increase in HbA1c. In contrast, each 10% increase in DMA% was associated with a 0.76% (0.24, 1.29) decrease in HbA1c. There was no evidence of an association of total urinary arsenic with prediabetes, diabetes, or HbA1c. These data suggest that a lower arsenic methylation capacity indicated by higher MMA% and lower DMA% in urine is associated with worse glycemic control and diabetes. Prospective, longitudinal studies are needed to evaluate the glycemic effects of low-level iAs exposure in urban populations.

Indexed as

ArsenicArsenicalsCacodylic AcidEnvironmental ExposureHumansNew York CityProspective StudiesArsenicArsenicalsCacodylic AcidclinicsHbA1cmetabolitesprediabetestype 2 diabetesurinary arsenic

Identifiers

PMID33916749
PMCPMC8038318
OpenAlexW3144915991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.